{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:38:38Z","timestamp":1784003918964,"version":"3.55.0"},"posted":{"date-parts":[[2023,8,25]]},"group-title":"Neurology","reference-count":84,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We investigated systemic biochemical changes in Alzheimer\u2019s disease (AD) by investigating the relationship between circulating plasma metabolites and both clinical and biomarker-assisted diagnosis of AD.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used an untargeted approach with liquid chromatography coupled to high-resolution mass spectrometry to measure exogenous and endogenous small molecule metabolites in plasma from 150 individuals clinically diagnosed with AD and 567 age-matched elderly without dementia of Caribbean Hispanic ancestry. Plasma biomarkers of AD were also measured including P-tau181, A\u03b240, A\u03b242, total tau, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP). Association of individual and co-expressed modules of metabolites were tested with the clinical diagnosis of AD, as well as biologically-defined AD pathological process based on P-tau181 and other biomarker levels.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    Over 4000 metabolomic features were measured with high accuracy. First principal component (PC) of lysophosphatidylcholines (lysoPC) that bind to or interact with docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and arachidonic acid (AHA) was associated with decreased risk of AD (OR=0.91 [0.89-0.96], p=2e-04). Restricted to individuals without an\n                    <jats:italic>APOE<\/jats:italic>\n                    \u03b5\n                    <jats:italic>4 allele<\/jats:italic>\n                    (OR=0.89 [0.84-0.94], p= 8.7e-05), the association remained. Among individuals carrying at least one\n                    <jats:italic>APOE<\/jats:italic>\n                    \u03b5\n                    <jats:italic>4<\/jats:italic>\n                    allele, PC4 of lysoPCs moderately increased risk of AD (OR=1.37 [1.16-1.6], p=1e-04). Essential amino acids including tyrosine metabolism pathways were enriched among metabolites associated with P-tau181 levels and heparan and keratan sulfate degradation pathways were associated with A\u03b242\/A\u03b240 ratio reflecting different pathways enriched in early and middle stages of disease.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>\n                    Our findings indicate that unbiased metabolic profiling can identify critical metabolites and pathways associated with \u03b2-amyloid and phosphotau pathology. We also observed an\n                    <jats:italic>APOE<\/jats:italic>\n                    \u03b5\n                    <jats:italic>4<\/jats:italic>\n                    dependent association of lysoPCs with AD and that biologically-based diagnostic criteria may aid in the identification of unique pathogenic mechanisms.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Graphical Abstract<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"23294581v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.1101\/2023.08.24.23294581","type":"posted-content","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T23:40:12Z","timestamp":1693006812000},"source":"Crossref","is-referenced-by-count":9,"title":["Lysophosphatidylcholines are associated with P-tau181 levels in early stages of Alzheimer\u2019s Disease"],"prefix":"10.64898","author":[{"given":"Vrinda","family":"Kalia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly","family":"Reyes-Dumeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Nandakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Lantigua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Medrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diones","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Honig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-9696","authenticated-orcid":false,"given":"Richard","family":"Mayeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5560-4085","authenticated-orcid":false,"given":"Badri N.","family":"Vardarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2023083009250497000_2023.08.24.23294581v1.1","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/brain\/awz384","article-title":"A multiomics approach to heterogeneity in Alzheimer\u2019s disease: focused review and roadmap","volume":"143","year":"2020","journal-title":"Brain"},{"key":"2023083009250497000_2023.08.24.23294581v1.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2016.25"},{"key":"2023083009250497000_2023.08.24.23294581v1.3","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/alz.12468","article-title":"Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer\u2019s disease","volume":"18","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2023083009250497000_2023.08.24.23294581v1.4","doi-asserted-by":"crossref","unstructured":"Wilkins, J.M. & Trushina, E . Application of Metabolomics in Alzheimer\u2019s Disease. Front Neurol 8, 719 (2017).","DOI":"10.3389\/fneur.2017.00719"},{"key":"2023083009250497000_2023.08.24.23294581v1.5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.neurobiolaging.2019.10.014","article-title":"Brain and blood metabolome for Alzheimer\u2019s dementia: findings from a targeted metabolomics analysis","volume":"86","year":"2020","journal-title":"Neurobiol Aging"},{"key":"2023083009250497000_2023.08.24.23294581v1.6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2478\/jtim-2022-0024","article-title":"Aberrant Energy Metabolism in Alzheimer\u2019s Disease","volume":"10","year":"2022","journal-title":"J Transl Int Med"},{"key":"2023083009250497000_2023.08.24.23294581v1.7","doi-asserted-by":"publisher","DOI":"10.20900\/immunometab20210034"},{"key":"2023083009250497000_2023.08.24.23294581v1.8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5534\/wjmh.200112","article-title":"Energy Metabolism and Aging","volume":"39","year":"2021","journal-title":"World J Mens Health"},{"key":"2023083009250497000_2023.08.24.23294581v1.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0072-x"},{"key":"2023083009250497000_2023.08.24.23294581v1.10","doi-asserted-by":"publisher","DOI":"10.1007\/BF02251132"},{"key":"2023083009250497000_2023.08.24.23294581v1.11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jalz.2017.09.011","article-title":"Evidence for brain glucose dysregulation in Alzheimer\u2019s disease","volume":"14","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2023083009250497000_2023.08.24.23294581v1.12","doi-asserted-by":"crossref","first-page":"e561","DOI":"10.1038\/tp.2015.52","article-title":"d-serine levels in Alzheimer\u2019s disease: implications for novel biomarker development","volume":"5","year":"2015","journal-title":"Transl Psychiatry"},{"key":"2023083009250497000_2023.08.24.23294581v1.13","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2262-17.2018"},{"key":"2023083009250497000_2023.08.24.23294581v1.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2003.11.009"},{"key":"2023083009250497000_2023.08.24.23294581v1.15","doi-asserted-by":"crossref","unstructured":"Wang, W. , Zhao, F. , Ma, X. , Perry, G. & Zhu, X . Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: recent advances. Mol Neurodegener 15, 30 (2020).","DOI":"10.1186\/s13024-020-00376-6"},{"key":"2023083009250497000_2023.08.24.23294581v1.16","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2174\/1570159X18666200525020259","article-title":"The Role of Mitochondrial Impairment in Alzheimers Disease Neurodegeneration: The Tau Connection","volume":"18","year":"2020","journal-title":"Curr Neuropharmacol"},{"key":"2023083009250497000_2023.08.24.23294581v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11813-6"},{"key":"2023083009250497000_2023.08.24.23294581v1.18","doi-asserted-by":"crossref","first-page":"662242","DOI":"10.3389\/fnins.2021.662242","article-title":"Glycolytic Metabolism, Brain Resilience, and Alzheimer\u2019s Disease","volume":"15","year":"2021","journal-title":"Front Neurosci"},{"key":"2023083009250497000_2023.08.24.23294581v1.19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14011310"},{"key":"2023083009250497000_2023.08.24.23294581v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2013.08.001"},{"key":"2023083009250497000_2023.08.24.23294581v1.21","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16344"},{"key":"2023083009250497000_2023.08.24.23294581v1.22","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1096\/fj.201801412R","article-title":"Role of phosphatidylcholine-DHA in preventing APOE4-associated Alzheimer\u2019s disease","volume":"33","year":"2019","journal-title":"FASEB J"},{"key":"2023083009250497000_2023.08.24.23294581v1.23","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5472792"},{"key":"2023083009250497000_2023.08.24.23294581v1.24","doi-asserted-by":"crossref","unstructured":"Savonije, K. & Weaver, D.F . The Role of Tryptophan Metabolism in Alzheimer\u2019s Disease. Brain Sci 13(2023).","DOI":"10.3390\/brainsci13020292"},{"key":"2023083009250497000_2023.08.24.23294581v1.25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3233\/JAD-210461","article-title":"Phenylalanine Metabolism Is Dysregulated in Human Hippocampus with Alzheimer\u2019s Disease Related Pathological Changes","volume":"83","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"2023083009250497000_2023.08.24.23294581v1.26","doi-asserted-by":"crossref","unstructured":"Whiley, L. , et al. Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer\u2019s disease. Alzheimers Res Ther 13, 20 (2021).","DOI":"10.1186\/s13195-020-00741-z"},{"key":"2023083009250497000_2023.08.24.23294581v1.27","doi-asserted-by":"crossref","first-page":"147481","DOI":"10.1016\/j.brainres.2021.147481","article-title":"Serum tyrosine is associated with better cognition in Lewy body dementia","volume":"1765","year":"2021","journal-title":"Brain Res"},{"key":"2023083009250497000_2023.08.24.23294581v1.28","first-page":"e12064","article-title":"Untargeted metabolomics reveal dysregulations in sugar, methionine, and tyrosine pathways in the prodromal state of AD","volume":"12","year":"2020","journal-title":"Alzheimers Dement (Amst"},{"key":"2023083009250497000_2023.08.24.23294581v1.29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02252924","article-title":"Amino acid concentrations in cerebrospinal fluid and plasma in Alzheimer\u2019s disease and healthy control subjects","volume":"2","year":"1990","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"2023083009250497000_2023.08.24.23294581v1.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-006-0409-8"},{"key":"2023083009250497000_2023.08.24.23294581v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2014.10.010"},{"key":"2023083009250497000_2023.08.24.23294581v1.32","doi-asserted-by":"publisher","DOI":"10.1021\/ac301243k"},{"key":"2023083009250497000_2023.08.24.23294581v1.33","doi-asserted-by":"crossref","unstructured":"Larsson, S.C. & Markus, H.S . Branched-chain amino acids and Alzheimer\u2019s disease: a Mendelian randomization analysis. Sci Rep 7, 13604 (2017).","DOI":"10.1038\/s41598-017-12931-1"},{"key":"2023083009250497000_2023.08.24.23294581v1.34","doi-asserted-by":"crossref","unstructured":"Li, H. , et al. Defect of branched-chain amino acid metabolism promotes the development of Alzheimer\u2019s disease by targeting the mTOR signaling. Biosci Rep 38(2018).","DOI":"10.1042\/BSR20180127"},{"key":"2023083009250497000_2023.08.24.23294581v1.35","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jalz.2016.01.008","article-title":"Increased susceptibility to metabolic dysregulation in a mouse model of Alzheimer\u2019s disease is associated with impaired hypothalamic insulin signaling and elevated BCAA levels","volume":"12","year":"2016","journal-title":"Alzheimers Dement"},{"key":"2023083009250497000_2023.08.24.23294581v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.01.020"},{"key":"2023083009250497000_2023.08.24.23294581v1.37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063644"},{"key":"2023083009250497000_2023.08.24.23294581v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.01.003"},{"key":"2023083009250497000_2023.08.24.23294581v1.39","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3233\/JAD-161118","article-title":"Therapeutics of Neurotransmitters in Alzheimer\u2019s Disease","volume":"57","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"2023083009250497000_2023.08.24.23294581v1.40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900014164","article-title":"The interplay of neurotransmitters in Alzheimer\u2019s disease","volume":"10","year":"2005","journal-title":"CNS Spectr"},{"key":"2023083009250497000_2023.08.24.23294581v1.41","doi-asserted-by":"crossref","unstructured":"Yang, Z. , Zou, Y. & Wang, L . Neurotransmitters in Prevention and Treatment of Alzheimer\u2019s Disease. Int J Mol Sci 24(2023).","DOI":"10.3390\/ijms24043841"},{"key":"2023083009250497000_2023.08.24.23294581v1.42","doi-asserted-by":"crossref","unstructured":"Li, Y. , et al. Implications of GABAergic Neurotransmission in Alzheimer\u2019s Disease. Front Aging Neurosci 8, 31 (2016).","DOI":"10.3389\/fnagi.2016.00031"},{"key":"2023083009250497000_2023.08.24.23294581v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2012.02.002"},{"key":"2023083009250497000_2023.08.24.23294581v1.44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3233\/JAD-190198","article-title":"Altered Redox State in Whole Blood Cells from Patients with Mild Cognitive Impairment and Alzheimer\u2019s Disease","volume":"71","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"2023083009250497000_2023.08.24.23294581v1.45","doi-asserted-by":"crossref","unstructured":"Holubiec, M.I. , Gellert, M. & Hanschmann, E.M . Redox signaling and metabolism in Alzheimer\u2019s disease. Front Aging Neurosci 14, 1003721 (2022).","DOI":"10.3389\/fnagi.2022.1003721"},{"key":"2023083009250497000_2023.08.24.23294581v1.46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3892\/br.2016.630","article-title":"Role of oxidative stress in Alzheimer\u2019s disease","volume":"4","year":"2016","journal-title":"Biomed Rep"},{"key":"2023083009250497000_2023.08.24.23294581v1.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-019-0132-6"},{"key":"2023083009250497000_2023.08.24.23294581v1.48","doi-asserted-by":"crossref","first-page":"e238214","DOI":"10.1001\/jamanetworkopen.2023.8214","article-title":"Evaluation of Plasma Biomarkers for A\/T\/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity","volume":"6","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2023083009250497000_2023.08.24.23294581v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"2023083009250497000_2023.08.24.23294581v1.50","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-011-5308-5"},{"key":"2023083009250497000_2023.08.24.23294581v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2013.05.057"},{"key":"2023083009250497000_2023.08.24.23294581v1.52","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp291"},{"key":"2023083009250497000_2023.08.24.23294581v1.53","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.6b01214"},{"key":"2023083009250497000_2023.08.24.23294581v1.54","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts034"},{"key":"2023083009250497000_2023.08.24.23294581v1.55","doi-asserted-by":"publisher","DOI":"10.1021\/es5002105"},{"key":"2023083009250497000_2023.08.24.23294581v1.56","doi-asserted-by":"crossref","unstructured":"Langfelder, P. & Horvath, S . WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).","DOI":"10.1186\/1471-2105-9-559"},{"key":"2023083009250497000_2023.08.24.23294581v1.57","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp356"},{"key":"2023083009250497000_2023.08.24.23294581v1.58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003123"},{"key":"2023083009250497000_2023.08.24.23294581v1.59","doi-asserted-by":"publisher","DOI":"10.1093\/advances\/nmaa024"},{"key":"2023083009250497000_2023.08.24.23294581v1.60","doi-asserted-by":"crossref","unstructured":"Law, S.H. , et al. An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases. Int J Mol Sci 20(2019).","DOI":"10.3390\/ijms20051149"},{"key":"2023083009250497000_2023.08.24.23294581v1.61","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P023309"},{"key":"2023083009250497000_2023.08.24.23294581v1.62","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00702-003-0007-9","article-title":"Decreased lysophosphatidylcholine\/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer\u2019s disease","volume":"110","year":"2003","journal-title":"J Neural Transm (Vienna"},{"key":"2023083009250497000_2023.08.24.23294581v1.63","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/0284186X.2011.648338","article-title":"Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC\/QTOF\/MS platform","volume":"51","year":"2012","journal-title":"Acta Oncol"},{"key":"2023083009250497000_2023.08.24.23294581v1.64","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.274142"},{"key":"2023083009250497000_2023.08.24.23294581v1.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2011.07.073"},{"key":"2023083009250497000_2023.08.24.23294581v1.66","first-page":"209","article-title":"Differential Pattern of Phospholipid Profile in the Temporal Cortex from E280A-Familiar and Sporadic Alzheimer\u2019s Disease Brains","volume":"61","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2023083009250497000_2023.08.24.23294581v1.67","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1471-4159.1998.70020786.x","article-title":"Phospholipid-metabolizing enzymes in Alzheimer\u2019s disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity","volume":"70","year":"1998","journal-title":"J Neurochem"},{"key":"2023083009250497000_2023.08.24.23294581v1.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2010.04.072"},{"key":"2023083009250497000_2023.08.24.23294581v1.69","first-page":"113","article-title":"Plasma metabolic profiling of mild cognitive impairment and Alzheimer\u2019s disease using liquid chromatography\/mass spectrometry","volume":"14","year":"2014","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"2023083009250497000_2023.08.24.23294581v1.70","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1097\/NEN.0000000000000116","article-title":"Lysophosphatidylcholine and amide as metabolites for detecting alzheimer disease using ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabonomics","volume":"73","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"2023083009250497000_2023.08.24.23294581v1.71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jprot.2014.01.014","article-title":"Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer\u2019s disease","volume":"104","year":"2014","journal-title":"J Proteomics"},{"key":"2023083009250497000_2023.08.24.23294581v1.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.12.008"},{"key":"2023083009250497000_2023.08.24.23294581v1.73","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/neup.12182","article-title":"Activated microglia in ischemic stroke penumbra upregulate MCP-1 and CCR2 expression in response to lysophosphatidylcholine derived from adjacent neurons and astrocytes","volume":"35","year":"2015","journal-title":"Neuropathology"},{"key":"2023083009250497000_2023.08.24.23294581v1.74","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neuroscience.2015.02.034","article-title":"Lysophosphatidylcholine increases the neurotoxicity of Alzheimer\u2019s amyloid beta1-42 peptide: role of oligomer formation","volume":"292","year":"2015","journal-title":"Neuroscience"},{"key":"2023083009250497000_2023.08.24.23294581v1.75","doi-asserted-by":"crossref","unstructured":"Knuplez, E. & Marsche, G . An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System. Int J Mol Sci 21(2020).","DOI":"10.3390\/ijms21124501"},{"key":"2023083009250497000_2023.08.24.23294581v1.76","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(94)00123-K"},{"key":"2023083009250497000_2023.08.24.23294581v1.77","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2213"},{"key":"2023083009250497000_2023.08.24.23294581v1.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2010.05.013"},{"key":"2023083009250497000_2023.08.24.23294581v1.79","doi-asserted-by":"crossref","unstructured":"Vardarajan, B. , et al. Differences in plasma metabolites related to Alzheimer\u2019s disease, APOE epsilo n4 status, and ethnicity. Alzheimers Dement (N Y) 6, e12025 (2020).","DOI":"10.1101\/2020.01.10.20016741"},{"key":"2023083009250497000_2023.08.24.23294581v1.80","doi-asserted-by":"crossref","unstructured":"Coughlan, G. , et al. APOE epsilon4 alters associations between docosahexaenoic acid and preclinical markers of Alzheimer\u2019s disease. Brain Commun 3, fcab085 (2021).","DOI":"10.1093\/braincomms\/fcab085"},{"key":"2023083009250497000_2023.08.24.23294581v1.81","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.neurobiolaging.2013.03.012","article-title":"Effects of a high-fat, high-cholesterol diet on brain lipid profiles in apolipoprotein E epsilon3 and epsilon4 knock-in mice","volume":"34","year":"2013","journal-title":"Neurobiol Aging"},{"key":"2023083009250497000_2023.08.24.23294581v1.82","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3233\/JAD-2011-111265","article-title":"The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol","volume":"28","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"2023083009250497000_2023.08.24.23294581v1.83","doi-asserted-by":"crossref","unstructured":"Miranda, A.M. , et al. Effects of APOE4 allelic dosage on lipidomic signatures in the entorhinal cortex of aged mice. Transl Psychiatry 12, 129 (2022).","DOI":"10.1038\/s41398-022-01881-6"},{"key":"2023083009250497000_2023.08.24.23294581v1.84","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00726-013-1583-0","article-title":"Literature review on the role of dietary protein and amino acids in cognitive functioning and cognitive decline","volume":"45","year":"2013","journal-title":"Amino Acids"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.08.24.23294581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:39:45Z","timestamp":1768505985000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.08.24.23294581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":84,"URL":"https:\/\/doi.org\/10.1101\/2023.08.24.23294581","relation":{},"subject":[],"published":{"date-parts":[[2023,8,25]]},"subtype":"preprint"}}